CoChat
Sign Up
Cited by 84

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer

Sharma, Madhu, Bakshi, Avijit Kumar, Mittapelly, Naresh, Gautam, Shalini, Marwaha, Disha, Rai, Nikhil, Singh, Neha, Tiwari, Pratiksha, Agarwal, Neha, Kumar, Ankit, Mishra, Prabhat Ranjan·2022·Journal of Controlled Release
DOI 10.1016/j.jconrel.2022.04.007
Open this paper in CoChat — free account

Abstract

The multi-dimensional challenge of drug resistance is one of the pivotal hindrances for cancer chemotherapy. A reductive approach to define and distinguish the main aspects of drug resistance, such as tumor growth kinetics about tumor micro-environment (tumor multifariousness), therapeutic pressure, physical barricades, irreversible genetic mutation, as well as role of the immune system, are the main causes of failure in cancer therapy are presented systematically. We are focusing on general approaches to reduce drug resistance: earlier diagnosis of tumors allowing for cancer halting; dynamic surveillance throughout treatment; the adding of new therapeutic strategies and improve pharmacodynamics precepts resulting in profound effects; and identification of cancerous cells repositories using high-throughput monitoring, as well as the interoperability of clinical- gene mapping statics are described in detail. These strategies could be potentially constructed for any tumor at any precise moment and used to guide therapy selection. Chemotherapeutic agents results in mild improved survival in clinical trials owing to several pathophysiologic obstacles, such as intra-tumoral dispersion, invasion & intra-cellular transportation. This review highlights recent advancements in developing new therapeutic innovations to combat drug resistance in cancer therapy by overcoming various barricades in the tumor microenvironment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2022.04.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 244

  1. Mansoori, 2017, The different mechanisms of cancer drug resistance: a brief review, Adv. Pharmaceut. Bull., 7, 339, 10.15171/apb.2017.041 · DOI
  2. Fleury, 2019, Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence, Nat. Commun., 10, 10.1038/s41467-019-10460-1 · DOI · Paper page
  3. Sakaue-Sawano, 2011, Drug-induced cell cycle modulation leading to cell-cycle arrest, nuclear mis-segregation, or endoreplication, BMC Cell Biol., 12, 2, 10.1186/1471-2121-12-2 · DOI
  4. Fair, 2014, Antibiotics and bacterial resistance in the 21st century, Perspect. Med. Chem., 25
  5. Aminov, 2010, A brief history of the antibiotic era: Lessons learned and challenges for the future, Front. Microbiol., 1, 1, 10.3389/fmicb.2010.00134 · DOI · Paper page
  6. Pérez-Herrero, 2015, Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy, Eur. J. Pharm. Biopharm., 93, 52, 10.1016/j.ejpb.2015.03.018 · DOI
  7. Yetsko, 2021, Molecular characterization of a marine turtle tumor epizootic, profiling external, internal and postsurgical regrowth tumors, Commun. Biol., 4, 1, 10.1038/s42003-021-01656-7 · DOI
  8. Malone, 2020, Molecular profiling for precision cancer therapies, Genome Med., 12, 1, 10.1186/s13073-019-0703-1 · DOI
  9. Ramos, 2015, Mechanism-based cancer therapy: resistance to therapy, therapy for resistance, Oncogene., 34, 3617, 10.1038/onc.2014.314 · DOI
  10. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  11. Kant Upadhyay, 2014, Evolution of new variants/mutants of JE virus, its effect on neurovirulence, antigenicity, host immune responses and disease transmission in endemic areas, J. Viruses., 2014, 1, 10.1155/2014/516904 · DOI
  12. Yang, 2015, Dual-ligand modified polymer-lipid hybrid nanoparticles for docetaxel targeting delivery to Her2/neu overexpressed human breast cancer cells, J. Biomed. Nanotechnol., 11, 1401, 10.1166/jbn.2015.2086 · DOI
  13. Oiseth, 2017, Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead, J. Cancer Metastasis Treatment, 3, 250, 10.20517/2394-4722.2017.41 · DOI
  14. Block, 2015, A broad-spectrum integrative prevention design for cancer prevention and therapy, Semin. Cancer Biol., 35, S276, 10.1016/j.semcancer.2015.09.007 · DOI
  15. Zhang, 2018, Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples, Acta Pharmacol. Sin., 39, 825, 10.1038/aps.2018.33 · DOI
  16. Yeh, 2020, Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances, Front. Chem., 8, 1, 10.3389/fchem.2020.00286 · DOI
  17. Navya, 2019, Current trends and challenges in cancer management and therapy using designer nanomaterials, Nano Convergence, 6, 10.1186/s40580-019-0193-2 · DOI
  18. Yu, 2021, Nanoparticles: a new approach to upgrade cancer diagnosis and treatment, Nanoscale Res. Lett., 16, 10.1186/s11671-021-03489-z · DOI · Paper page
  19. Jin, 2020, Application of nanotechnology in cancer diagnosis and therapy - A mini-review, Int. J. Med. Sci., 17, 2964, 10.7150/ijms.49801 · DOI
  20. Soares, 2018, Nanomedicine: principles, properties, and regulatory issues, Front. Chem., 6, 1, 10.3389/fchem.2018.00360 · DOI
  21. OECD International Futures Programme, 2007, Small sizes that matter: opportunities and risks of nanotechnologies, Allianz., 46
  22. Henke, 2020, Extracellular matrix in the tumor microenvironment and its impact on cancer therapy, Front. Mol. Biosci., 6, 1, 10.3389/fmolb.2019.00160 · DOI · Paper page
  23. Roarty, 2021, Laboratory models for investigating breast cancer therapy resistance and metastasis, Front. Oncol., 11, 1, 10.3389/fonc.2021.645698 · DOI
  24. Ndagi, 2020, Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug design, RSC Adv., 10, 18451, 10.1039/D0RA01484B · DOI
  25. Nedeljkovi, 2019, Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge., Cell, 8, 957, 10.3390/cells8090957 · DOI
  26. Block, 2015, Designing a broad-spectrum integrative approach for cancer prevention and treatment, Semin. Cancer Biol., 35, S276, 10.1016/j.semcancer.2015.09.007 · DOI
  27. Murciano-Goroff, 2020, The future of cancer immunotherapy: microenvironment-targeting combinations, Cell Res., 30, 507, 10.1038/s41422-020-0337-2 · DOI
  28. Mehta, 2010, Predictive and prognostic molecular markers for cancer medicine, Therap. Adv. Med. Oncol., 2, 125, 10.1177/1758834009360519 · DOI
  29. Rivlin, 2011, Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis, Genes Cancer., 2, 466, 10.1177/1947601911408889 · DOI · Paper page
  30. Falzone, 2018, Evolution of cancer pharmacological treatments at the turn of the third millennium, Front. Pharmacol., 9, 1300, 10.3389/fphar.2018.01300 · DOI
  31. Dasari, 2014, Cisplatin in cancer therapy: molecular mechanisms of action, Eur. J. Pharmacol., 740, 364, 10.1016/j.ejphar.2014.07.025 · DOI · Paper page
  32. Li, 2020, A deep learning diagnostic platform for diffuse large B-cell lymphoma with high accuracy across multiple hospitals, Nat. Commun., 11, 10.1038/s41467-020-19817-3 · DOI
  33. Savage, 2020, Chemotherapy curability in leukemia, lymphoma, germ cell tumors and gestational malignancies: a reflection of the unique physiology of their cells of origin, Front. Genet., 11, 1, 10.3389/fgene.2020.00426 · DOI
  34. Hartge, 2007, Environmental and behavioral factors and the risk of non-Hodgkin lymphoma, Cancer Epidemiol. Biomark. Prev., 16, 367, 10.1158/1055-9965.EPI-07-0031 · DOI
  35. Cho, 2018, Modeling the chemotherapy-induced selection of drug-resistant traits during tumor growth, J. Theor. Biol., 436, 120, 10.1016/j.jtbi.2017.10.005 · DOI
  36. Leighow, 2020, Multi-scale predictions of drug resistance epidemiology identify design principles for rational drug design, Cell Rep., 30, 3951, 10.1016/j.celrep.2020.02.108 · DOI
  37. Suzuki, 2014, Prediction of antibiotic resistance by gene expression profiles, Nat. Commun., 5, 10.1038/ncomms6792 · DOI
  38. Wang, 2019, Drug resistance and combating drug resistance in cancer, Cancer Drug Resistance, 2, 141
  39. Raguz, 2008, Resistance to chemotherapy: new treatments and novel insights into an old problem, Br. J. Cancer, 99, 387, 10.1038/sj.bjc.6604510 · DOI
  40. Lu, 2020, Development of therapeutic antibodies for the treatment of diseases, J. Biomed. Sci., 27, 1, 10.1186/s12929-019-0592-z · DOI
  41. Hansen, 2017, How to use a chemotherapeutic agent when resistance to it threatens the patient, PLoS Biol., 15, 1, 10.1371/journal.pbio.2001110 · DOI
  42. Food, 2020, Immuno-oncology agents for cancer therapy, Pharm. J., 1
  43. Jo, 2018, Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development, Theranostics., 8, 5259, 10.7150/thno.29098 · DOI
  44. Khalaf, 2021, Aspects of the tumor microenvironment involved in immune resistance and drug resistance, Front. Immunol., 12, 1, 10.3389/fimmu.2021.656364 · DOI
  45. Fu, 2015, Spatial heterogeneity in drug concentrations can facilitate the emergence of resistance to cancer therapy, PLoS Comput. Biol., 11, 1, 10.1371/journal.pcbi.1004142 · DOI
  46. Dos Santos, 2019, Photodynamic therapy in cancer treatment - an update review, J. Cancer Metastasis Treatment, 2019, 10.20517/2394-4722.2018.83 · DOI
  47. Cowan, 2000, A study of interval breast cancer within the NHS breast screening programme, J. Clin. Pathol., 53, 140, 10.1136/jcp.53.2.140 · DOI
  48. Welch, 2016, Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness, N. Engl. J. Med., 375, 1438, 10.1056/NEJMoa1600249 · DOI
  49. Houssami, 2017, The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening, Npj Breast Cancer., 3, 1, 10.1038/s41523-017-0014-x · DOI
  50. Castorina, 2009, Tumor growth instability and its implications for chemotherapy, Cancer Res., 69, 8507, 10.1158/0008-5472.CAN-09-0653 · DOI
  51. Simon, 2006, The Norton - Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens, Nat. Clin. Pract. Oncol., 3, 406, 10.1038/ncponc0560 · DOI
  52. López, 2019, Nonlinear cancer chemotherapy: modelling the Norton-Simon hypothesis, Commun. Nonlinear Sci. Numer. Simul., 70, 307, 10.1016/j.cnsns.2018.11.006 · DOI
  53. Vaghi, 2020, Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors, PLoS Comput. Biol., 16, 1, 10.1371/journal.pcbi.1007178 · DOI
  54. Retsky, 1990, Is Gompertzian or exponential kinetics a valid description of individual human cancer growth?, Med. Hypotheses, 33, 95, 10.1016/0306-9877(90)90186-I · DOI
  55. Johnson, 2019, Cancer cell population growth kinetics at low densities deviate from the exponential growth model and suggest an Allee effect, PLoS Biol., 17, 1, 10.1371/journal.pbio.3000399 · DOI
  56. Pourhasanzade, 2019, A cellular automata model of chemotherapy effects on tumour growth: targeting cancer and immune cells, Math. Comput. Model. Dyn. Syst., 25, 63, 10.1080/13873954.2019.1571515 · DOI
  57. Mir, 2014, Highly sensitive quantitative imaging for monitoring single cancer cell growth kinetics and drug response, PLoS One, 9, 10.1371/journal.pone.0089000 · DOI
  58. Geng, 2017, Prediction of treatment response for combined chemo- and radiation therapy for non-small cell lung cancer patients using a bio-mathematical model, Sci. Rep., 7, 1, 10.1038/s41598-017-13646-z · DOI
  59. Hudis, 2000, Dose-dense chemotherapy for breast cancer: the story so far, Br. J. Cancer, 82, 1897
  60. Gray, 2019, Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials, Lancet, 393, 1440, 10.1016/S0140-6736(18)33137-4 · DOI
  61. Nurgali, 2018, Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?, Front. Pharmacol., 9, 1, 10.3389/fphar.2018.00245 · DOI
  62. Mokhtari, 2017, Combination therapy in combating cancer systematic review: combination therapy in combating cancer background, Oncotarget., 8, 38022, 10.18632/oncotarget.16723 · DOI · Paper page
  63. Lim, 2019, Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy, J. Hematol. Oncol., 12, 1, 10.1186/s13045-019-0818-2 · DOI
  64. Mitchell, 2015, Chromothripsis: a new mechanism for rapid karyotype evolution, Rev. Adv First., 14, 1
  65. Joubert, 2020, Environmental health research in Africa: important progress and promising opportunities, Front. Genet., 10, 1, 10.3389/fgene.2019.01166 · DOI
  66. Garcia-Martinez, 2021, Epigenetic mechanisms in breast cancer therapy and resistance, Nat. Commun., 12, 1, 10.1038/s41467-021-22024-3 · DOI
  67. De Angelis, 2019, Stem cell plasticity and dormancy in the development of cancer therapy resistance, Front. Oncol., 9, 1, 10.3389/fonc.2019.00626 · DOI
  68. Sever, 2015, Signal transduction in cancer, Cold Spring Harbor Perspect. Med., 5, 10.1101/cshperspect.a006098 · DOI
  69. Daniel, 2019, Temozolomide induced hypermutation in glioma: Evolutionary mechanisms and therapeutic opportunities, Front. Oncol., 9, 1, 10.3389/fonc.2019.00041 · DOI
  70. Tan, 2020, Management of glioblastoma: state of the art and future directions, CA Cancer J. Clin., 70, 299
  71. Maedler-Kron, 2016, Hematopoietic stem cell transplantation, Pathol. Transplant.:Practical Diagnostic Approach., 401, 10.1007/978-3-319-29683-8_10 · DOI
  72. Jamal-Hanjani, 2015, Translational implications of tumor heterogeneity, Clin. Cancer Res., 21, 1258, 10.1158/1078-0432.CCR-14-1429 · DOI
  73. Pongor, 2020, Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting, Sci. Rep., 10, 1, 10.1038/s41598-020-71382-3 · DOI
  74. Brady, 2017, Combating subclonal evolution of resistant cancer phenotypes, Nat. Commun., 8, 10.1038/s41467-017-01174-3 · DOI
  75. von Loga, 2020, Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer, Nat. Commun., 11, 1
  76. Reiter, 2019, An analysis of genetic heterogeneity in untreated cancers, Nat. Rev. Cancer, 19, 639, 10.1038/s41568-019-0185-x · DOI
  77. Haibe, 2020, Resistance mechanisms to anti-angiogenic therapies in cancer, Front. Oncol., 10, 10.3389/fonc.2020.00221 · DOI
  78. Jing, 2019, Role of hypoxia in cancer therapy by regulating the tumor microenvironment, Mol. Cancer, 18, 1, 10.1186/s12943-019-1089-9 · DOI · Paper page
  79. Al-Abd, 2017, Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – a review, J. Adv. Res., 8, 591, 10.1016/j.jare.2017.06.006 · DOI
  80. Magnussen, 2021, Vascular normalisation as the stepping stone into tumour microenvironment transformation, Br. J. Cancer, 125, 324, 10.1038/s41416-021-01330-z · DOI · Paper page
  81. Lin, 2015, Treatment of brain metastases, J. Clin. Oncol., 33, 3475, 10.1200/JCO.2015.60.9503 · DOI
  82. Chicas-Sett, 2019, Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a systematic review, Int. J. Mol. Sci., 20, 10.3390/ijms20092173 · DOI
  83. Wang, 2017, Role of tumor microenvironment in tumorigenesis, J. Cancer, 8, 761, 10.7150/jca.17648 · DOI · Paper page
  84. Whiteside, 2008, The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008 Oct;27(45):5904.ss, Oncogene., 27, 5904, 10.1038/onc.2008.271 · DOI · Paper page
  85. Labani-Motlagh, 2020, The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses, Front. Immunol., 11, 1, 10.3389/fimmu.2020.00940 · DOI
  86. Barrueto, 2020, Resistance to checkpoint inhibition in cancer immunotherapy, Transl. Oncol., 13, 100738, 10.1016/j.tranon.2019.12.010 · DOI
  87. Bai, 2020, Mechanisms of cancer resistance to immunotherapy, Front. Oncol., 10, 1, 10.3389/fonc.2020.01290 · DOI
  88. Wang, 2011, Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology, Cell Cycle, 10, 57, 10.4161/cc.10.1.14449 · DOI
  89. Hosein Mohimani, 2017, Dorrestein3, RAS-targeted therapies: is the undruggable drugged?, Physiol. Behav., 176, 139
  90. Grivennikov, 2011, Immunity, inflammation, and cancer, Cell., 140, 883, 10.1016/j.cell.2010.01.025 · DOI · Paper page
  91. Gonzalez, 2018, Roles of the immune system in cancer: from tumor initiation to metastatic progression, Genes Dev., 32, 1267, 10.1101/gad.314617.118 · DOI · Paper page
  92. Sologuren, 2014, Immune effects of high dose radiation treatment: Implications of ionizing radiation on the development of bystander and abscopal effects, Transl. Cancer Res., 3, 18
  93. Turner, 2009, Epigenetic responses to environmental change and their evolutionary implications, Philos. Trans. Roy. Soc. B: Biol. Sci., 364, 3403, 10.1098/rstb.2009.0125 · DOI
  94. Lacal, 2018, Epigenetic inheritance: concepts, mechanisms and perspectives, Front. Mol. Neurosci., 11, 1, 10.3389/fnmol.2018.00292 · DOI
  95. Leonetti, 2019, Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer, Br. J. Cancer, 121, 725, 10.1038/s41416-019-0573-8 · DOI
  96. Bhullar, 2018, Kinase-targeted cancer therapies: progress, challenges and future directions, Mol. Cancer, 17, 1, 10.1186/s12943-018-0804-2 · DOI
  97. Tan, 2019, Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies, OncoTargets Therapy., 12, 635, 10.2147/OTT.S189391 · DOI
  98. Davis, 2014, Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention, Oncotarget, 5, 4603, 10.18632/oncotarget.2209 · DOI
  99. Saad, 2017, Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291), OncoTargets Therapy., 10, 1757, 10.2147/OTT.S100650 · DOI
  100. Kregel, 2013, Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer, PLoS One, 8, 10.1371/journal.pone.0053701 · DOI
  101. Rathkopf, 2018, Apalutamide for the treatment of prostate cancer, Expert. Rev. Anticancer. Ther., 18, 823, 10.1080/14737140.2018.1503954 · DOI
  102. Korde, 2021, Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline, J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol., 39, 1485, 10.1200/JCO.20.03399 · DOI
  103. Beane, 2017, Genomic approaches to accelerate cancer interception, Lancet Oncol., 18, e494, 10.1016/S1470-2045(17)30373-X · DOI
  104. Nagai, 2017, Cancer prevention from the perspective of global cancer burden patterns, J. Thoracic Dis., 9, 448, 10.21037/jtd.2017.02.75 · DOI
  105. Purandare, 2015, Imaging of lung cancer: implications on staging and management, Ind. J. Radiol. Imag., 25, 109, 10.4103/0971-3026.155831 · DOI
  106. Deveson, 2021, Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology, Nat. Biotechnol., 10.1038/s41587-021-00857-z · DOI
  107. Gorgannezhad, 2018, Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies, Lab Chip, 18, 1174, 10.1039/C8LC00100F · DOI
  108. Elazezy, 2018, Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management, Comput. Struct. Biotechnol. J., 16, 370, 10.1016/j.csbj.2018.10.002 · DOI
  109. Casiraghi, 2020, ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA, Bioinformatics., 36, 2665, 10.1093/bioinformatics/btaa016 · DOI
  110. Baylin, 2016, Epigenetic determinants of cancer, Cold Spring Harb. Perspect. Biol., 8, 1, 10.1101/cshperspect.a019505 · DOI
  111. Li, 2020, Reliable tumor detection by whole-genome methylation sequencing of cell-free DNA in cerebrospinal fluid of pediatric medulloblastoma, Sci. Adv., 6, 10.1126/sciadv.abb5427 · DOI
  112. Yoo, 2018, New directions in the study and treatment of metastatic cancer, Front. Oncol., 8, 1, 10.3389/fonc.2018.00258 · DOI
  113. Orth, 2019, Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches, Radiat. Oncol., 14, 1, 10.1186/s13014-019-1345-6 · DOI
  114. Blom, 2017, Predictive value of ex vivo chemosensitivity assays for individualized cancer chemotherapy: a meta-analysis, SLAS Technol., 22, 306, 10.1177/2472630316686297 · DOI
  115. Dahlgren, 2020, Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: a drug-delivery perspective, Molecules, 25, 10.3390/molecules25122861 · DOI
  116. Tamura, 2019, Trastuzumab deruxtecan (DS-8201a)in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study, Lancet Oncol., 20, 816, 10.1016/S1470-2045(19)30097-X · DOI
  117. Nakada, 2019, The latest research and development into the antibody–drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy, Chem. Pharm. Bull., 67, 173, 10.1248/cpb.c18-00744 · DOI
  118. Ogitani, 2016, DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1, Clin. Cancer Res., 22, 5097, 10.1158/1078-0432.CCR-15-2822 · DOI
  119. Le, 2016, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
  120. Chocarro de Erauso, 2020, Resistance to PD-L1/PD-1 blockade immunotherapy. a tumor-intrinsic or tumor-extrinsic phenomenon?, Front. Pharmacol., 11, 1, 10.3389/fphar.2020.00441 · DOI
  121. LaCasse, 2008, IAP-targeted therapies for cancer, Oncogene., 27, 6252, 10.1038/onc.2008.302 · DOI
  122. Matthew Holderfield, 2014, Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond, Bone, 23, 1
  123. Zhong, 2021, Small molecules in targeted cancer therapy: advances, challenges, and future perspectives, Signal Transduct. Targeted Therapy, 6, 10.1038/s41392-021-00572-w · DOI
  124. Klement, 2002, Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts, Clin. Cancer Res., 8, 221
  125. Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res., 64, 2343, 10.1158/0008-5472.CAN-03-3856 · DOI
  126. Fuentes, 2011, Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism, Breast Cancer Res., 13, R54, 10.1186/bcr2888 · DOI
  127. Al-Horani, 2020, Potential therapeutic roles for direct factor xa inhibitors in coronavirus infections, Am. J. Cardiovasc. Drugs, 20, 525, 10.1007/s40256-020-00438-6 · DOI
  128. Karaiskos, 2014, Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches, Expert. Opin. Pharmacother., 15, 1351, 10.1517/14656566.2014.914172 · DOI
  129. Domchek, 2015, Gynecologic Oncology Ef fi cacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy, Gynecol. Oncol., 10
  130. Nassar, 2021, Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction, Clin. Epigenetics, 13, 1, 10.1186/s13148-021-01095-5 · DOI
  131. Li, 2021, Current status of ctDNA in precision oncology for hepatocellular carcinoma, J. Exp. Clin. Cancer Res., 40, 1, 10.1186/s13046-021-02032-3 · DOI
  132. Hau, 2020, Targeting epstein-barr virus in nasopharyngeal carcinoma, Front. Oncol., 10, 1, 10.3389/fonc.2020.00600 · DOI
  133. Dai, 2016, Genetic and epigenetic landscape of nasopharyngeal carcinoma, Chin. Clin. Oncol., 5, 1, 10.21037/cco.2016.03.06 · DOI
  134. Society, 2021, PARP inhibitors show promise as initial treatment for ovarian cancer the trouble with DNA repair PRIMA : niraparib as maintenance, Therapy, 1
  135. Mirza, 2018, Latest clinical evidence and further development of PARP inhibitors in ovarian cancer, Ann. Oncol., 29, 1366, 10.1093/annonc/mdy174 · DOI
  136. Macdonald, 2016, Breast cancer breast cancer, J. R. Soc. Med., 70, 515
  137. Yang, 2019, Targeting PI3K in cancer: mechanisms and advances in clinical trials, Mol. Cancer, 18, 1, 10.1186/s12943-019-0954-x · DOI
  138. Eradat, 2019, Venetoclax for the treatment of chronic lymphocytic leukemia, Curr. Hematol. Malignancy Rep., 14, 469, 10.1007/s11899-019-00539-3 · DOI
  139. Anagnostou, 2019, Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer, Cancer Res., 79, 1214, 10.1158/0008-5472.CAN-18-1127 · DOI
  140. Coombes, 2019, Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence, Clin. Cancer Res., 25, 4255, 10.1158/1078-0432.CCR-18-3663 · DOI
  141. Danny, 2017, The future of cancer treatment: immunomodulation, CARs and combination immunotherapy, Physiol. Behav., 176, 139
  142. Ansell, 2012, Positron emission tomographic scans in lymphoma: convention and controversy, Mayo Clin. Proc., 87, 571, 10.1016/j.mayocp.2012.03.006 · DOI
  143. Cheng, 2016, Circulating tumor DNA: A promising biomarker in the liquid biopsy of cancer, Oncotarget, 7, 48832, 10.18632/oncotarget.9453 · DOI
  144. Jung, 2020, Advances in the assessment of minimal residual disease in mantle cell lymphoma, J. Hematol. Oncol., 13, 127, 10.1186/s13045-020-00961-8 · DOI
  145. Zhang, 2019, The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis, Mol. Cancer, 18, 1, 10.1186/s12943-019-0989-z · DOI
  146. Garcia-Murillas, 2015, Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Sci. Transl. Med., 7, 1, 10.1126/scitranslmed.aab0021 · DOI
  147. Thress, 2015, EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291, Lung Cancer, 90, 509, 10.1016/j.lungcan.2015.10.004 · DOI
  148. Kitazono, 2019, Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients, Cancer Sci., 110, 3350, 10.1111/cas.14153 · DOI
  149. Saarenheimo, 2019, The value of liquid biopsies for guiding therapy decisions in non-small cell lung cancer, Front. Oncol., 9, 1, 10.3389/fonc.2019.00129 · DOI
  150. Chabon, 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients, Nat. Commun., 7
  151. Yagawa, 2017, Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery, J. Cancer Metastasis Treatment, 3, 218, 10.20517/2394-4722.2017.35 · DOI
  152. Manstein, 2014, Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops, Curr. Signal Transduct. Therapy., 8, 193, 10.2174/1574362409666140206221931 · DOI
  153. Lee, 2020, Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity, Int. J. Mol. Sci., 21, 1
  154. Ursan, 2015, Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors, J. Manag. Care Pharm., 21, 114
  155. Omoto, 2015, Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects, Cancer Sci., 106, 337, 10.1111/cas.12613 · DOI
  156. Lucía Benito-Jardon, 2019, Resistance to MAPK inhibitors in melanoma involves activation of the IGF1R – MEK5 – Erk5 pathway, Cancer Res., 79, 2244, 10.1158/0008-5472.CAN-18-2762 · DOI
  157. Rani, 2019, Endocrine resistance in hormone receptor positive breast cancer – from mechanism to therapy, Front. Endocrinol., 10, 1, 10.3389/fendo.2019.00245 · DOI
  158. Robin Urquhart, 2013, Exploring the usefulness of two conceptual frameworks for understanding how organizational factors influence innovation implementation in cancer care, J. Contin. Educ. Health Prof., 33, 48, 10.1002/chp.21165 · DOI
  159. Vora, 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors, Cancer Cell, 26, 136, 10.1016/j.ccr.2014.05.020 · DOI · Paper page
  160. Hosein Mohimani, 2017, 3, NTRK fusion-positive cancers and TRK inhibitor therapy, Physiol. Behav., 176, 139
  161. Li, 2020, Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer, Front. Pharmacol., 11, 1
  162. Jenkins, 2018, Mechanisms of resistance to immune checkpoint inhibitors, Br. J. Cancer, 118, 9, 10.1038/bjc.2017.434 · DOI · Paper page
  163. Zhang, 2020, The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis, Ann. Palliative Med., 9, 4081, 10.21037/apm-20-2011 · DOI
  164. Bonser, 1946, The genetics of cancer, Br. Med. Bull., 4, 207, 10.1093/oxfordjournals.bmb.a072749 · DOI
  165. Csermely, 2005, The efficiency of multi-target drugs: the network approach might help drug design, Trends Pharmacol. Sci., 26, 178, 10.1016/j.tips.2005.02.007 · DOI · Paper page
  166. ud Din, 2017, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int. J. Nanomedicine, 12, 7291, 10.2147/IJN.S146315 · DOI
  167. Scioli Montoto, 2020, Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects, Front. Mol. Biosci., 7, 1, 10.3389/fmolb.2020.587997 · DOI
  168. Lombardo, 2019, Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine, J. Nanomater., 2019, 10.1155/2019/3702518 · DOI · Paper page
  169. Haider, 2020, Nanostructured lipid carriers for delivery of chemotherapeutics: a review, Pharmaceutics, 12, 10.3390/pharmaceutics12030288 · DOI
  170. Ferrari, 2005, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer, 5, 161, 10.1038/nrc1566 · DOI · Paper page
  171. Liu, 2016, The smart drug delivery system and its clinical potential, Theranostics., 6, 1306, 10.7150/thno.14858 · DOI · Paper page
  172. Nguyen, 2020, Ultrahigh high-strain-rate superplasticity in a nanostructured high-entropy alloy, Nat. Commun., 11, 1, 10.1038/s41467-020-16601-1 · DOI
  173. Ha, 2018, Recent advances incorporating superparamagnetic nanoparticles into immunoassays, ACS Appl. Nano Mater., 1, 512, 10.1021/acsanm.7b00025 · DOI
  174. Alfarouk, 2015, Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp, Cancer Cell Int., 15, 1, 10.1186/s12935-015-0221-1 · DOI
  175. Helleday, 2008, DNA repair pathways as targets for cancer therapy, nature reviews, Cancer., 8, 193
  176. de Angelis, 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil, Int. J. Oncol., 24, 1279
  177. Sayan, 2009, SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer, Proc. Natl. Acad. Sci. U. S. A., 106, 14884, 10.1073/pnas.0902042106 · DOI
  178. Huang, 2021, GE11 peptide conjugated liposomes for EGFR-targeted and chemophotothermal combined anticancer therapy, Bioinorg. Chem. Appl., 2021, 10.1155/2021/5534870 · DOI
  179. Housman, 2014, Drug resistance in cancer: an overview, Cancers., 6, 1769, 10.3390/cancers6031769 · DOI · Paper page
  180. Samanta, 2019, Gemcitabine combination nano therapies for pancreatic cancer, Pharmaceutics., 11, 1, 10.3390/pharmaceutics11110574 · DOI
  181. Smith, 2021, Targeted cancer therapies, Am. Fam. Physician, 103, 155
  182. Nedeljkovi, 2019, Mechanisms of chemotherapy resistance in triple-negative breast cancer—howwe can rise to the challenge, Cell., 8, 957, 10.3390/cells8090957 · DOI
  183. Li, 2016, Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy, Proc. Natl. Acad. Sci. U. S. A., 113, 4164, 10.1073/pnas.1522080113 · DOI
  184. Razak, 2021, Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview, Cancers., 13, 1, 10.3390/cancers13030400 · DOI
  185. Pandey, 2018, Multifunctional glycoconjugate assisted nanocrystalline drug delivery for tumor targeting and permeabilization of lysosomal-mitochondrial membrane, ACS Appl. Mater. Interfaces, 10, 16964, 10.1021/acsami.7b18699 · DOI
  186. Bhattacharjee, 2019, Polymeric Nanoparticles, Principles Nanomed., 195, 10.1201/9780429031236-8 · DOI
  187. Song, 2018, Current development of biodegradable polymeric materials for biomedical applications, drug design, Develop. Therapy., 12, 3117, 10.2147/DDDT.S165440 · DOI
  188. Li, 2015, Multipronged design of light-triggered nanoparticles to overcome cisplatin resistance for efficient ablation of resistant tumor, ACS Nano, 9, 9626, 10.1021/acsnano.5b05097 · DOI
  189. Endres, 2011, Self-assembled biodegradable amphiphilic PEG-PCL-lPEI triblock copolymers at the borderline between micelles and nanoparticles designed for drug and gene delivery, Biomaterials., 32, 7721, 10.1016/j.biomaterials.2011.06.064 · DOI
  190. Gogoi, 2020, Preparation, characterization and cytotoxic applications of curcumin-(±) α-lipoic acid coloaded phosphorylated chitosan nanoparticles in MDA MB 231 breast cancer cell line, Polym. Adv. Technol., 31, 2827, 10.1002/pat.5009 · DOI
  191. Su, 2020, Systemic review of biodegradable nanomaterials in nanomedicine, Nanomaterials, 10, 10.3390/nano10040656 · DOI
  192. Wang, 2021, Targeted delivery of quercetin by nanoparticles based on chitosan sensitizing paclitaxel-resistant lung cancer cells to paclitaxel, Mater. Sci. Eng. C, 119, 111442, 10.1016/j.msec.2020.111442 · DOI
  193. Kaul, 2018, Role of nanotechnology in cosmeceuticals: a review of recent advances, J. Pharmaceut., 2018, 1, 10.1155/2018/3420204 · DOI
  194. Zhou, 2016, Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy, Nano Lett., 16, 3268, 10.1021/acs.nanolett.6b00820 · DOI
  195. Urandur, 2018, Anisamide-anchored lyotropic nano-liquid crystalline particles with AIE effect: a smart optical beacon for tumor imaging and therapy, ACS Appl. Mater. Interfaces, 10, 12960, 10.1021/acsami.7b19109 · DOI
  196. Yang, 2020, Lipid-based drug delivery nanoplatforms for colorectal cancer therapy, Nanomaterials., 10, 1, 10.3390/nano10071424 · DOI
  197. Bozzuto, 2015, Liposomes as nanomedical devices, Int. J. Nanomedicine, 10, 975, 10.2147/IJN.S68861 · DOI
  198. Wei, 2013, Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo, Nano Lett., 13, 2528, 10.1021/nl400586t · DOI
  199. Lähdesmäki, 2009, Phospholipase A2-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH, Atherosclerosis., 207, 352, 10.1016/j.atherosclerosis.2009.04.031 · DOI
  200. Abbasi, 2014, Dendrimers: synthesis, applications, and properties, Nanoscale Res. Lett., 9, 1, 10.1186/1556-276X-9-247 · DOI

200 of 244 shown

Cited by

Sorted by citations

See all 84

Metadata

Authors
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., & Mishra, P. R.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2022-06
Volume
346
Pages
43-70
ISSN
0168-3659
DOI
10.1016/j.jconrel.2022.04.007
Cited by
84
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review